Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Jerry Roy

Interventional Cardiology Bowling Green, KY Medical Doctor

NPI 1487826814 CMS profile 1328874

201 Park St, Bowling Green, KY 42101

Open in the dashboard

General payments

$8,145

435 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$172,189 paid to institutions, not to them · program years 2023–2025

Through program year 2025, Jerry Roy of Bowling Green, KY is reported in the CMS Open Payments database as having received $8,145 across 435 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $172,189 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 52nd percentile of Interventional Cardiology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $829 39
2024 General $856 50
2023 General $1,506 79
2022 General $1,623 96
2021 General $924 53
2020 General $396 30
2019 General $2,011 88

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Jerry Roy
  • Interventional Cardiology median
  • Middle half of Interventional Cardiology
  • National median

In program year 2025, general payments to Jerry Roy were reported at $829. Among 6,173 Interventional Cardiology profiles paid that year, the median was $1,092 and the middle half received between $366 and $3,019.

Show as a table
Year Jerry Roy Interventional Cardiology median Middle half National median
2019 $2,011 $1,097 $329–$3,048 $163
2020 $396 $473 $161–$1,480 $114
2021 $924 $677 $233–$1,827 $132
2022 $1,623 $978 $333–$2,724 $149
2023 $1,506 $1,136 $382–$2,986 $160
2024 $856 $1,181 $395–$3,326 $164
2025 $829 $1,092 $366–$3,019 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Novartis Pharmaceuticals Corporation $1,297 83 payments
  2. Janssen Pharmaceuticals, Inc $827 67 payments
  3. Medtronic, Inc. $827 38 payments
  4. Medtronic Vascular, Inc. $796 22 payments
  5. Pfizer Inc. $671 45 payments
  6. Amgen Inc. $322 20 payments
  7. AstraZeneca Pharmaceuticals LP $321 15 payments
  8. Abiomed $306 9 payments
  9. Boehringer Ingelheim Pharmaceuticals, Inc. $282 17 payments
  10. Boston Scientific Corporation $271 9 payments
  11. Other $2,224 110 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $7,811 433 payments
  2. Travel and Lodging $319 1 payment
  3. Education $14 1 payment
Products named General payments · program years 2019–2025
  1. XARELTO $827 67 payments
  2. CoreValve Evolut $750 19 payments
  3. LEQVIO $611 37 payments
  4. COREVALVE EVOLUT R $595 30 payments
  5. ENTRESTO Cardiovascular $586 37 payments
  6. ELIQUIS $526 37 payments
  7. Repatha $322 20 payments
  8. ENTRESTO Cardiology/Vascular Diseases $265 13 payments
  9. BRILINTA $254 10 payments
  10. VERQUVO $241 16 payments
  11. Other $4,146 203 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 40 drugs

Part D claims

2,697

Median for Interventional Cardiology: 2,236

Drug cost

$493,970

Median for Interventional Cardiology: $380,412

Branded share of claims

33%

Median for Interventional Cardiology: 27.8%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 324 $311,592
Brilinta Ticagrelor Brand 72 $42,251
Xarelto Rivaroxaban Brand 36 $41,702
Entresto Sacubitril/Valsartan Brand 37 $28,750
Jardiance Empagliflozin Brand 26 $17,232
Multaq Dronedarone Hcl Brand 19 $16,769
Repatha Sureclick Evolocumab Brand 23 $13,999
Ranolazine Er Ranolazine Brand 62 $3,431
Metoprolol Succinate Generic 283 $2,735
Amiodarone Hcl Generic 59 $1,958

The 10 drugs with the highest cost, of 40 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 4,694 Part D prescribers listed as Interventional Cardiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 118 billing codes

Paid by Medicare

$445,666

Of which drugs: $53,943

Medicare patients

1,553

Average age 75

Services billed

13,912

772 women, 781 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 55%
Ischemic heart disease 53%
Diabetes 39%
Heart failure 37%
Atrial fibrillation 37%
Chronic kidney disease 30%
COPD 27%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, regadenoson, 0.1 mg J2785 Office 119 476 $2,149
Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml Q9967 Office 14 1,600 $160

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 14 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
LEQVIO
  • Novartis Pharmaceuticals Corporation $113
$113 — —
RYBELSUS
  • Novo Nordisk Inc $66
$66 — —
Ozempic
  • Novo Nordisk Inc $66
$66 — —
VERQUVO
  • Merck Sharp & Dohme Corporation $63
$63 — —
Arcalyst
  • Kiniksa Pharmaceuticals International, plc $55
$55 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 14 in the dashboard with a free account

Records

435 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record